Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Biogen’s main MS assets facing increasing competition and further losses in the MS market

Biogen recently announced Food and Drug Administration (FDA) approval of its new intramuscular (IM) injection route of administration for Plegridy (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS). This new formulation will enable Biogen to expand its MS portfolio, while also reducing the side effects from the subcutaneous way of administration […]
Read more

Vaccine trials necessary to assess effectiveness against fast-spreading new COVID-19 variants, says GlobalData

While governments are ramping up vaccination programs, continued research into the effectiveness of the vaccines is imperative to prevent a worsening of the impact of COVID-19, says GlobalData, a leading data and analytics company. Mohamed Abukar, MSc, Clinical Trials Analyst at GlobalData, comments: “The fast-spreading new COVID-19 variants may reduce the protective effects offered by […]
Read more

Pharmaceutical manufacturers to benefit from Biden’s marijuana legalization plans, says GlobalData

President Joe Biden brings a significant likelihood of federal marijuana reform, one of his key campaign promises. Amidst the ongoing opioid crisis, legalizing cannabis at the federal level will lead many clinicians and patients to reduce their use of highly addictive opioids. The legalizing will also create significant business opportunities for pharmaceutical manufacturers of both […]
Read more

Tonix Pharma eyes significant share in metabolic market with intranasal drug licensing deal, says GlobalData

Tonix Pharmaceuticals (Tonix) has recently announced a licensing deal with Katana Pharmaceuticals for its intranasal potentiated oxytocin with a view to expand its application into metabolic disorders such as insulin resistance, diabetes and obesity. Tonix had originally purchased oxytocin-potentiated therapy from Trigemina in June 2020, with a promising pre-clinical data demonstrating efficacy for the intranasal […]
Read more

World Cancer Day 2021: Too early to assess full impact of COVID-19 on oncology development and treatment, says GlobalData

With the COVID-19 pandemic contributing to delays in clinical trial enrollment and routine cancer screening and treatment, many barriers have arisen preventing patients from seeking and receiving timely care for cancer. The full impact of COVID-19 on the oncology development and treatment landscape one year later is currently unknown, and it will be some time […]
Read more

New strategies implemented in hepatocellular carcinoma market will provide more treatment options to physicians

The implementation of new strategies will turn the hepatocellular carcinoma (HCC) market into a land of opportunity for manufacturers, leading to a wave of new entrants. Additionally, regulatory incentives such as orphan drug designations and fast track approvals have led to a dynamic market, says GlobalData, a leading data and analytics company. Mandana Emamzadeh, PhD, […]
Read more

COVID-19 disrupted clinical trials due to slow recruitment continue to grow

Since June 2020, the number of total disrupted trials has been falling slowly; however, this has leveled off in October 2020. Despite this, the number of clinical trials that have resumed continues to rise. The majority of current trial disruptions are due to trials impacted by slow enrollment, which continue to gradually increase, says GlobalData, a leading data and analytics company. Brooke Wilson, Associate Director, Trials Intelligence at GlobalData, comments: “This implies that although sponsors and contract service […]
Read more

Sonder’s European expansion plans highlight success amid the pandemic

Sonder’s European expansion plans have not been halted due to COVID-19 as the company is now exploring the Spanish market, with a keen eye on Madrid and Barcelona. Sonder is in a position to expand in 2021 due to a successful 2020 – in relation to the vast majority of other major lodging companies. Its awareness to react to the new traveler need of extended stays allowed the company to navigate successfully through the first […]
Read more

10 key pharma themes reveal that COVID-19, remote patient monitoring and drug pricing and reimbursement to have greatest impact on industry in 2021, says GlobalData

• COVID-19 will continue to impact all aspects of the pharma value chain in 2021 • Drug development activities, in particular clinical trials, will have the biggest impact on industry success in 2021 • 70% of leading pharma executives are optimistic that the industry will continue to grow over the next 12 months COVID-19 has had a transformational effect on every […]
Read more

Key companies in Japan’s melanoma market need to establish stronger digital support across all channels, finds GlobalData

The melanoma therapeutics market in Japan comprises of drugs approved for chemotherapy, immunotherapy, and targeted therapy. Among these, immunotherapy and targeted therapy are the leading class of drugs. The digital support from existing players available for patients through branded and unbranded channels is not equally distributed as there is a lack of presence or weaker […]
Read more

J&J’s COVID-19 vaccine best used to control outbreak, while Novavax’s vaccine is better for overall protection, says GlobalData

Following the news that Novavax’s COVID-19 vaccine shows 89.3% while Johnson & Johnson’s (J&J) demonstrated 66% efficacy; Michael Breen, PhD, Director of Infectious Diseases and Ophthalmology and Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offer their view: “J&J’s COVID-19 vaccine will be the agent of choice for […]
Read more

Across pharmaceutical value chain drug development process will experience biggest impact from COVID-19 in 2021

Despite seriously affecting the ability to carry out clinical research, COVID-19 is also proving to be a catalyst that may transform the drug development process, with technological innovations taking center stage in driving this change, says GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘The State of the Biopharmaceutical Industry 2021’, reveals that the drug development process will face the biggest impact from COVID-19 in 2021, as confirmed by 32% (N=63) out of 198 pharmaceutical industry professionals. […]
Read more

Xeljanz safety data in Rheumatoid Arthritis could mean headaches for all JAK inhibitors

Following Pfizer’s recent announcement of co-primary endpoint results from ORAL Surveillance (NCT02092467) in rheumatoid arthritis (RA) patients with cardiovascular (CV) risk factors; Rose Joachim, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “These results signal troubles ahead for Xeljanz and potentially other JAK inhibitor products. The ORAL Surveillance trial first came under scrutiny in early 2019, when Pfizer had to modify the protocol […]
Read more
1 … 71 72 73 74 75 … 110